Luvadaxistat

Luvadaxistat (TAK-831) is an orally active, highly selective, potent D-amino acid oxidase (DAAO) inhibitor. Luvadaxistat inhibits oxidative deamination of D-serine via the human recombinant DAAO enzyme with an IC50 of 14 nM. Luvadaxistat significantly increases D-serine levels in the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat has the potential for schizophrenia research[1][2].

Product Specifications

CAS Number

[1425511-32-5]

Product Name Alternative

TAK-831

UNSPSC

12352005

Target

Xanthine Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/luvadaxistat.html

Purity

99.89

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(O)=CC(CCC2=CC=C(C(F)(F)F)C=C2)=NN1

Molecular Formula

C13H11F3N2O2

Molecular Weight

284.23

References & Citations

[1]Wang H, Norton J, Xu L, DeMartinis N, Sen R, Shah A, Farmer J, Lynch D. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol. 2021 Jun;8 (6) :1343-1352.|[2]Rosa Fradley, et al. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.